Is OLMA or AMLX more profitable?

Olema Pharmaceuticals' return on equity of -48.26% beat Amylyx Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Olema Pharmaceuticals N/A -48.26% -43.04% Amylyx Pharmaceuticals N/A -52.92% -48.53%

Does the media refer more to OLMA or AMLX?

In the previous week, Amylyx Pharmaceuticals had 39 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 42 mentions for Amylyx Pharmaceuticals and 3 mentions for Olema Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 0.71 beat Olema Pharmaceuticals' score of 0.67 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Olema Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amylyx Pharmaceuticals 14 Very Positive mention(s) 7 Positive mention(s) 12 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend OLMA or GMTX?

Olema Pharmaceuticals currently has a consensus target price of $42.40, suggesting a potential upside of 296.63%. Given Olema Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Olema Pharmaceuticals is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Olema Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.71 Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation & earnings, OLMA or GMTX?

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Olema Pharmaceuticals N/A N/A -$162.45M -$2.12 N/A Gemini Therapeutics N/A N/A -$71.87M -$1.00 N/A

Is OLMA or GMTX more profitable?

Gemini Therapeutics' return on equity of -38.78% beat Olema Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Olema Pharmaceuticals N/A -48.26% -43.04% Gemini Therapeutics N/A -38.78% -35.88%

Does the media refer more to OLMA or GMTX?

In the previous week, Olema Pharmaceuticals had 2 more articles in the media than Gemini Therapeutics. MarketBeat recorded 3 mentions for Olema Pharmaceuticals and 1 mentions for Gemini Therapeutics. Gemini Therapeutics' average media sentiment score of 0.75 beat Olema Pharmaceuticals' score of 0.67 indicating that Gemini Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Olema Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Gemini Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor OLMA or ABCL?

In the previous week, AbCellera Biologics had 2 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 5 mentions for AbCellera Biologics and 3 mentions for Olema Pharmaceuticals. AbCellera Biologics' average media sentiment score of 1.03 beat Olema Pharmaceuticals' score of 0.67 indicating that AbCellera Biologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Olema Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AbCellera Biologics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to OLMA or VCYT?

In the previous week, Veracyte had 7 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 10 mentions for Veracyte and 3 mentions for Olema Pharmaceuticals. Veracyte's average media sentiment score of 1.29 beat Olema Pharmaceuticals' score of 0.67 indicating that Veracyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Olema Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veracyte 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor OLMA or QURE?

In the previous week, Olema Pharmaceuticals had 1 more articles in the media than uniQure. MarketBeat recorded 3 mentions for Olema Pharmaceuticals and 2 mentions for uniQure. Olema Pharmaceuticals' average media sentiment score of 0.67 beat uniQure's score of 0.48 indicating that Olema Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Olema Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive uniQure 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Olema Pharmaceuticals (OLMA) Competitors

$10.69 -0.21 (-1.93%)

As of 08/21/2026 04:00 PM Eastern

Compare

OLMA vs. AMLX, GMTX, ABCL, VCYT, and QURE

Should you buy Olema Pharmaceuticals stock or one of its competitors? Olema Pharmaceuticals's main competitors and comparable companies include Amylyx Pharmaceuticals (AMLX), Gemini Therapeutics (GMTX), AbCellera Biologics (ABCL), Veracyte (VCYT), and uniQure (QURE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Olema Pharmaceuticals compare to Amylyx Pharmaceuticals?

Olema Pharmaceuticals (NASDAQ:OLMA) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation, risk and media sentiment.

Amylyx Pharmaceuticals has higher revenue and earnings than Olema Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.12	N/A
Amylyx Pharmaceuticals	$87.37M	49.30	-$144.74M	-$1.43	N/A

In the previous week, Amylyx Pharmaceuticals had 39 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 42 mentions for Amylyx Pharmaceuticals and 3 mentions for Olema Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 0.71 beat Olema Pharmaceuticals' score of 0.67 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Olema Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amylyx Pharmaceuticals	14 Very Positive mention(s)	7 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Olema Pharmaceuticals' return on equity of -48.26% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Olema Pharmaceuticals	N/A	-48.26%	-43.04%
Amylyx Pharmaceuticals	N/A	-52.92%	-48.53%

91.8% of Olema Pharmaceuticals shares are held by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. 12.6% of Olema Pharmaceuticals shares are held by company insiders. Comparatively, 10.9% of Amylyx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Olema Pharmaceuticals presently has a consensus target price of $42.40, suggesting a potential upside of 296.63%. Amylyx Pharmaceuticals has a consensus target price of $36.25, suggesting a potential downside of 6.23%. Given Olema Pharmaceuticals' higher possible upside, equities research analysts plainly believe Olema Pharmaceuticals is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

Olema Pharmaceuticals has a beta of 2.03, meaning that its stock price is 103% more volatile than the broader market. Comparatively, Amylyx Pharmaceuticals has a beta of -0.21, meaning that its stock price is 121% less volatile than the broader market.

Summary

Amylyx Pharmaceuticals beats Olema Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Olema Pharmaceuticals compare to Gemini Therapeutics?

Olema Pharmaceuticals (NASDAQ:OLMA) and Gemini Therapeutics (NASDAQ:GMTX) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk and valuation.

Gemini Therapeutics' return on equity of -38.78% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Olema Pharmaceuticals	N/A	-48.26%	-43.04%
Gemini Therapeutics	N/A	-38.78%	-35.88%

Olema Pharmaceuticals currently has a consensus target price of $42.40, suggesting a potential upside of 296.63%. Given Olema Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Olema Pharmaceuticals is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

91.8% of Olema Pharmaceuticals shares are held by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are held by institutional investors. 12.6% of Olema Pharmaceuticals shares are held by insiders. Comparatively, 12.9% of Gemini Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Olema Pharmaceuticals has a beta of 2.03, meaning that its share price is 103% more volatile than the broader market. Comparatively, Gemini Therapeutics has a beta of -0.12, meaning that its share price is 112% less volatile than the broader market.

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.12	N/A
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A

In the previous week, Olema Pharmaceuticals had 2 more articles in the media than Gemini Therapeutics. MarketBeat recorded 3 mentions for Olema Pharmaceuticals and 1 mentions for Gemini Therapeutics. Gemini Therapeutics' average media sentiment score of 0.75 beat Olema Pharmaceuticals' score of 0.67 indicating that Gemini Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Olema Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Gemini Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Olema Pharmaceuticals beats Gemini Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Olema Pharmaceuticals compare to AbCellera Biologics?

Olema Pharmaceuticals (NASDAQ:OLMA) and AbCellera Biologics (NASDAQ:ABCL) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.

Olema Pharmaceuticals has a beta of 2.03, suggesting that its share price is 103% more volatile than the broader market. Comparatively, AbCellera Biologics has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market.

In the previous week, AbCellera Biologics had 2 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 5 mentions for AbCellera Biologics and 3 mentions for Olema Pharmaceuticals. AbCellera Biologics' average media sentiment score of 1.03 beat Olema Pharmaceuticals' score of 0.67 indicating that AbCellera Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Olema Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AbCellera Biologics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AbCellera Biologics has higher revenue and earnings than Olema Pharmaceuticals. AbCellera Biologics is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.12	N/A
AbCellera Biologics	$75.13M	46.20	-$146.41M	-$0.54	N/A

Olema Pharmaceuticals has a net margin of 0.00% compared to AbCellera Biologics' net margin of -248.83%. AbCellera Biologics' return on equity of -17.49% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Olema Pharmaceuticals	N/A	-48.26%	-43.04%
AbCellera Biologics	-248.83%	-17.49%	-12.36%

91.8% of Olema Pharmaceuticals shares are owned by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are owned by institutional investors. 12.6% of Olema Pharmaceuticals shares are owned by insiders. Comparatively, 28.4% of AbCellera Biologics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Olema Pharmaceuticals presently has a consensus target price of $42.40, indicating a potential upside of 296.63%. AbCellera Biologics has a consensus target price of $12.83, indicating a potential upside of 13.37%. Given Olema Pharmaceuticals' higher probable upside, research analysts plainly believe Olema Pharmaceuticals is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

AbCellera Biologics beats Olema Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Olema Pharmaceuticals compare to Veracyte?

Olema Pharmaceuticals (NASDAQ:OLMA) and Veracyte (NASDAQ:VCYT) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Olema Pharmaceuticals currently has a consensus price target of $42.40, indicating a potential upside of 296.63%. Veracyte has a consensus price target of $54.33, indicating a potential upside of 28.42%. Given Olema Pharmaceuticals' higher possible upside, analysts clearly believe Olema Pharmaceuticals is more favorable than Veracyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Veracyte	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82

In the previous week, Veracyte had 7 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 10 mentions for Veracyte and 3 mentions for Olema Pharmaceuticals. Veracyte's average media sentiment score of 1.29 beat Olema Pharmaceuticals' score of 0.67 indicating that Veracyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Olema Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veracyte	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Olema Pharmaceuticals has a beta of 2.03, meaning that its stock price is 103% more volatile than the broader market. Comparatively, Veracyte has a beta of 1.95, meaning that its stock price is 95% more volatile than the broader market.

91.8% of Olema Pharmaceuticals shares are held by institutional investors. 12.6% of Olema Pharmaceuticals shares are held by company insiders. Comparatively, 1.6% of Veracyte shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Veracyte has a net margin of 20.37% compared to Olema Pharmaceuticals' net margin of 0.00%. Veracyte's return on equity of 9.26% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Olema Pharmaceuticals	N/A	-48.26%	-43.04%
Veracyte	20.37%	9.26%	8.61%

Veracyte has higher revenue and earnings than Olema Pharmaceuticals. Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.12	N/A
Veracyte	$517.15M	6.58	$66.35M	$1.41	30.01

Summary

Veracyte beats Olema Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Olema Pharmaceuticals compare to uniQure?

Olema Pharmaceuticals (NASDAQ:OLMA) and uniQure (NASDAQ:QURE) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends.

Olema Pharmaceuticals has higher earnings, but lower revenue than uniQure. uniQure is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.12	N/A
uniQure	$18.67M	179.69	-$198.97M	-$4.01	N/A

Olema Pharmaceuticals currently has a consensus price target of $42.40, indicating a potential upside of 296.63%. uniQure has a consensus price target of $65.00, indicating a potential upside of 34.38%. Given Olema Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Olema Pharmaceuticals is more favorable than uniQure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
uniQure	1 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, Olema Pharmaceuticals had 1 more articles in the media than uniQure. MarketBeat recorded 3 mentions for Olema Pharmaceuticals and 2 mentions for uniQure. Olema Pharmaceuticals' average media sentiment score of 0.67 beat uniQure's score of 0.48 indicating that Olema Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Olema Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
uniQure	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

91.8% of Olema Pharmaceuticals shares are owned by institutional investors. Comparatively, 78.8% of uniQure shares are owned by institutional investors. 12.6% of Olema Pharmaceuticals shares are owned by insiders. Comparatively, 4.7% of uniQure shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Olema Pharmaceuticals has a net margin of 0.00% compared to uniQure's net margin of -1,350.73%. Olema Pharmaceuticals' return on equity of -48.26% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Olema Pharmaceuticals	N/A	-48.26%	-43.04%
uniQure	-1,350.73%	-111.96%	-29.01%

Olema Pharmaceuticals has a beta of 2.03, meaning that its share price is 103% more volatile than the broader market. Comparatively, uniQure has a beta of 0.92, meaning that its share price is 8% less volatile than the broader market.

Summary

Olema Pharmaceuticals beats uniQure on 12 of the 15 factors compared between the two stocks.

Get Olema Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OLMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OLMA vs. The Competition

Export

Metric	Olema Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$935.35M	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	11.08%
P/E Ratio	-5.04	11.62	272.60	24.25
Price / Sales	N/A	1,338.15	618.96	99.05
Price / Cash	N/A	105.14	78.62	53.99
Price / Book	2.17	16.80	13.05	6.20
Net Income	-$162.45M	-$12.50M	$3.47B	$348.59M
7 Day Performance	0.56%	3.29%	2.09%	0.08%
1 Month Performance	-8.94%	8.23%	6.64%	3.88%
1 Year Performance	85.59%	55.05%	25.02%	16.98%

Olema Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OLMA Olema Pharmaceuticals	2.0729 of 5 stars	$10.69 -1.9%	$42.40 +296.6%	+85.6%	$935.35M	N/A	N/A	70	Options Volume
AMLX Amylyx Pharmaceuticals	1.7938 of 5 stars	$32.51 +51.7%	$26.13 -19.6%	+315.7%	$3.64B	$87.37M	N/A	200	Trending News Analyst Forecast Analyst Revision High Trading Volume
GMTX Gemini Therapeutics	N/A	$78.84 -1.5%	N/A	+33.6%	$3.42B	N/A	N/A	30	News Coverage
ABCL AbCellera Biologics	2.3014 of 5 stars	$11.08 -1.1%	$12.83 +15.9%	+157.9%	$3.39B	$66.17M	N/A	500	Positive News
VCYT Veracyte	4.3764 of 5 stars	$41.19 -2.1%	$54.33 +31.9%	+36.5%	$3.31B	$561.90M	29.21	790	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OLMA) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Olema Pharmaceuticals (OLMA) Competitors

OLMA vs. AMLX, GMTX, ABCL, VCYT, and QURE

How does Olema Pharmaceuticals compare to Amylyx Pharmaceuticals?

Summary

How does Olema Pharmaceuticals compare to Gemini Therapeutics?

Summary

How does Olema Pharmaceuticals compare to AbCellera Biologics?

Summary

How does Olema Pharmaceuticals compare to Veracyte?

Summary

How does Olema Pharmaceuticals compare to uniQure?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OLMA vs. The Competition

Olema Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Olema Pharmaceuticals (OLMA) Competitors

OLMA vs. AMLX, GMTX, ABCL, VCYT, and QURE

How does Olema Pharmaceuticals compare to Amylyx Pharmaceuticals?

Which has preferable earnings & valuation, OLMA or AMLX?

Does the media refer more to OLMA or AMLX?

Is OLMA or AMLX more profitable?

Do institutionals & insiders hold more shares of OLMA or AMLX?

Do analysts recommend OLMA or AMLX?

Which has more volatility & risk, OLMA or AMLX?

Summary

How does Olema Pharmaceuticals compare to Gemini Therapeutics?

Is OLMA or GMTX more profitable?

Do analysts recommend OLMA or GMTX?

Do institutionals and insiders hold more shares of OLMA or GMTX?

Which has more risk and volatility, OLMA or GMTX?

Which has stronger valuation & earnings, OLMA or GMTX?

Does the media refer more to OLMA or GMTX?

Summary

How does Olema Pharmaceuticals compare to AbCellera Biologics?

Which has more risk and volatility, OLMA or ABCL?

Does the media favor OLMA or ABCL?

Which has better valuation & earnings, OLMA or ABCL?

Is OLMA or ABCL more profitable?

Do institutionals and insiders believe in OLMA or ABCL?

Do analysts prefer OLMA or ABCL?

Summary

How does Olema Pharmaceuticals compare to Veracyte?

Do analysts prefer OLMA or VCYT?

Does the media refer more to OLMA or VCYT?

Which has more risk & volatility, OLMA or VCYT?

Do institutionals & insiders believe in OLMA or VCYT?

Is OLMA or VCYT more profitable?

Which has higher earnings and valuation, OLMA or VCYT?

Summary

How does Olema Pharmaceuticals compare to uniQure?

Which has higher valuation & earnings, OLMA or QURE?

Do analysts recommend OLMA or QURE?

Does the media favor OLMA or QURE?

Do insiders & institutionals believe in OLMA or QURE?

Is OLMA or QURE more profitable?

Which has more volatility and risk, OLMA or QURE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OLMA vs. The Competition

Olema Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools